Introduction

Background Information
The lactic Acid Bacteria

Limitations of L.Acidophilus
As The Species of choice
In Lactobacillus Therapy

Benefits of Lactobacillus
Sporogenes as a probiotic

Clinical Studies

Gastro-Intestinal & Associated Effects

Hypercholestrolemic Effects

Use of L.Sporenges in the treatment of Non-Specific Vaginitis

Clinical trials in the treatment of Aphthous Stomatitis & Glossitis

L.Sporogenes as a
Veterinary probiotic

Toxicological aspects
of Lactospore

Testing procedures & Stability

Summary

References

Glossary

Contact Us

Home


Use of L. sporogenes in the treatment of non-specific vaginitis

Non-specific vaginitis is caused by a variety of pathogens including staphylococci, streptococci, pneumococci and E. coli. It may also be induced by a variety of causes including chemicals, drugs, surgical procedures, trauma and foreign bodies. L. sporogenes administration to increase the vaginal acidity by the action of the lactic acid (produced by Lactobacillus) on glycogen in the vaginal epithelial tissues was adopted in a clinical trial on 44 patients26. The patients were divided into two groups:

Group 1: Twelve patients suffering from leucorrhea (white discharge) following cervical surgery.

Group 2 : Thirty two patients with nonspecific vaginitis without previous therapy. Of these, 26 were in the reproductive age and 6 were menopausal. The change in vaginal pH following treatment with MYCONIPÒ (L. sporogenes tablets) over a period of two weeks is shown in the Figure 5.2:

Most of the cases showing persistently alkaline pH were post-menopausal, where acid could not be produced in sufficient amounts due to low substrate glycogen levels. Glycogen levels depend upon circulating estrogen.

The response to treatment in both groups is tabulated below:

 

Type of response

Number of cases

Group 1 Group 2 Total
1. Quick response and complete relief 8 (67%) 26 (81.25%) 34 (77.25%)
2. Delayed response but complete relief 2 (16.5%) 4 (12.5%) 6 (13.60%)
3. Improvement but not complete relief 2 (15.5%) 2 (6.25%) 2 (9.15%)
4. No relief 0 0 0
Total 12 (100%) 32 (100%) 44 (100%)

In comparison with a clinical trial using M.T.P. vaginal pessaries containing broxyquinoline and brobenzoxeldine where only 26.67% of cases studied were cured. It can be seen that L. sporogenes therapy is the better alternative in the treatment of non-specific vaginitis. L. sporogenes therapy provided complete relief to 91% of the patients and partial relief to the remaining 9%.

      sslogo.gif (1636 bytes)
©  Sabinsa Corporation 2000